NCT00085904View on ClinicalTrials.gov

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2004

Conditions
Solid Tumor CancerLymphoma
Interventions
DRUG

SB-485232

Trial Locations (3)

46202

GSK Investigational Site, Indianapolis

02215

GSK Investigational Site, Boston

15213-2584

GSK Investigational Site, Pittsburgh

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY